You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Preclinical Efficacy And Safety Evaluation Of Graphene Nanoparticle-based Magneti

    SBC: Theragnostic Technologies Inc.            Topic: NIDDK

    Abstract This STTR phase 1 proposal investigates the safety and efficacy of a novel high-performance carbon nanostructure-based magnetic resonance imaging (MRI) contrast agent for the imaging and monitoring of patients with renal failure. Every year, in the US, approximately 20 million people are treated for mild to severe renal failure. A significant number of cases (greater than 50%) related to ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  2. Image-Based Quantification and Analysis of Longitudinal Lung Nodule Deformations

    SBC: KITWARE INC            Topic: NIBIB

    DESCRIPTION (provided by applicant): Image-based evaluation of pathologies over time is complicated by variability in image acquisition and patient positioning, deformations due to respiratory and cardiac motion, and the clinical standard in radiology of comparing unaligned images. This application proposes a computational method for longitudinal image analysis that captures, illustrates and quant ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  3. In-situ, real-time oxygen sensor to monitor the long-term efficacy of aerobicall

    SBC: ChromoSense LLC            Topic: NIEHS

    DESCRIPTION (provided by applicant): Groundwater and soil contamination has been associated with higher incidence of birth defects and cancer. Monitored natural attenuation of contaminants via biodegradation has proven effective in lowering contaminant levels, but these processes depend critically on dissolved oxygen levels. This project proposes to develop a robust oxygen sensor compound with che ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  4. Zonular Capture Accommodative-Disaccommodative Intraocular Lens System

    SBC: Z Lens LLC            Topic: NEI

    DESCRIPTION (provided by applicant): We are developing an accommodative - disaccommodative intraocular lens implant (ADIOL) system based on a novel concept of capturing zonular tension and transmitting it unimpeded to a dynamically position intraocular lens system. This is made possible by a zonular capture haptic (ZCH) apparatus. This apparatus lends itself equally well to several possible combin ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  5. The Retroject Device: A Novel Approach to Glaucoma Drug Delivery

    SBC: RETROJECT, INC.            Topic: NEI

    PROJECT ABSTRACT Glaucoma is a common neurodegenerative disease which is the 2nd leading cause of blindness in the United States. With the aging baby boomer population, these numbers will continue to increase exponentially over the next few decades. With glaucomatous progression, there is ultimately damage to the optic nerve which results in peripheral vision loss. It has been shown in many prior ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  6. Topical Therapeutic to Promote Healing of Chronic Wounds

    SBC: Phoenicia Biosciences, Inc.            Topic: NIGMS

    DESCRIPTION (provided by applicant): Chronic refractory, or non-healing, wounds or ulcerations of the extremities represent a major medical condition affecting millions of patients. A chronic wound is defined as a wound that does not show signs of significant healing, or progresses, after use of topical/surgical treatment measures for six months. Non-healing wounds affect 6.5 million patients, aff ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  7. Early Warning system for detecting pre-eclampsia

    SBC: CONVERGENT ENGINEERING, INC.            Topic: NICHD

    DESCRIPTION (provided by applicant): Preeclampsia, a hypertensive disorder of pregnancy, is a leading cause of maternal and neonatal morbidity and mortality around the world, responsible for approximately 76,000 maternal and 500,000 infant deaths per year.As a heterogeneous and poorly understood disorder, its pathogenesis and possible treatments are an area of active research. While the majority o ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  8. human Microvessel Culture System (hMCS)

    SBC: ANGIOMICS, INC.            Topic: NHLBI

    DESCRIPTION (provided by applicant): Human Microvessel Culture System (hMCS) Angiogenesis-targeting therapies, either inhibiting or promoting new vessel growth, have the potential for treating numerous diseases including cancer, eye diseases, cardiac and peripheral vascular disease, skin disorders, fibro-proliferative diseases, and inflammatory conditions such as arthritis. Furthermore, growing ev ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  9. Pharmacological Targeting of Endothelial Dysfunction in Atherogenesis

    SBC: RIPARIAN PHARMACEUTICALS INC            Topic: NHLBI

    DESCRIPTION (provided by applicant): Pharmacological Targeting of Endothelial Dysfunction in Atherogenesis Cardiovascular disease is the leading cause of morbidity and mortality in the United States and is an emerging epidemic world-wide. In particular, atherosclerosis is a life-threatening disease strongly associated with risk factors such as elevated cholesterol levels, high blood pressure and d ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  10. Selective HDAC1/2 inhibitors for hemoglobinopathies

    SBC: ACETYLON PHARMACEUTICALS, INC.            Topic: NHLBI

    DESCRIPTION (provided by applicant): The long term goal of this project is a selective Histone Deacetylase 1 and 2 (HDAC1/2) inhibitor for the treatment of patients with the beta-hemoglobinopathies sickle cell anemia and beta- thalassemia. An estimated 400,000 children are born each year with one of these hemoglobin disorders. Few treatments exist to alleviate the symptoms of hemoglobinopathies an ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government